244 related articles for article (PubMed ID: 20332234)
1. Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance.
To K; Fotovati A; Reipas KM; Law JH; Hu K; Wang J; Astanehe A; Davies AH; Lee L; Stratford AL; Raouf A; Johnson P; Berquin IM; Royer HD; Eaves CJ; Dunn SE
Cancer Res; 2010 Apr; 70(7):2840-51. PubMed ID: 20332234
[TBL] [Abstract][Full Text] [Related]
2. The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells.
Dhillon J; Astanehe A; Lee C; Fotovati A; Hu K; Dunn SE
Oncogene; 2010 Nov; 29(47):6294-300. PubMed ID: 20802512
[TBL] [Abstract][Full Text] [Related]
3. Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers.
Stratford AL; Reipas K; Hu K; Fotovati A; Brough R; Frankum J; Takhar M; Watson P; Ashworth A; Lord CJ; Lasham A; Print CG; Dunn SE
Stem Cells; 2012 Jul; 30(7):1338-48. PubMed ID: 22674792
[TBL] [Abstract][Full Text] [Related]
4. Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1).
Reipas KM; Law JH; Couto N; Islam S; Li Y; Li H; Cherkasov A; Jung K; Cheema AS; Jones SJ; Hassell JA; Dunn SE
Oncotarget; 2013 Feb; 4(2):329-45. PubMed ID: 23593654
[TBL] [Abstract][Full Text] [Related]
5. P-cadherin is coexpressed with CD44 and CD49f and mediates stem cell properties in basal-like breast cancer.
Vieira AF; Ricardo S; Ablett MP; Dionísio MR; Mendes N; Albergaria A; Farnie G; Gerhard R; Cameselle-Teijeiro JF; Seruca R; Schmitt F; Clarke RB; Paredes J
Stem Cells; 2012 May; 30(5):854-64. PubMed ID: 22389315
[TBL] [Abstract][Full Text] [Related]
6. YB-1 transforms human mammary epithelial cells through chromatin remodeling leading to the development of basal-like breast cancer.
Davies AH; Reipas KM; Pambid MR; Berns R; Stratford AL; Fotovati A; Firmino N; Astanehe A; Hu K; Maxwell C; Mills GB; Dunn SE
Stem Cells; 2014 Jun; 32(6):1437-50. PubMed ID: 24648416
[TBL] [Abstract][Full Text] [Related]
7. Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells.
Finkbeiner MR; Astanehe A; To K; Fotovati A; Davies AH; Zhao Y; Jiang H; Stratford AL; Shadeo A; Boccaccio C; Comoglio P; Mertens PR; Eirew P; Raouf A; Eaves CJ; Dunn SE
Oncogene; 2009 Mar; 28(11):1421-31. PubMed ID: 19151767
[TBL] [Abstract][Full Text] [Related]
8. Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel.
Fujita T; Ito K; Izumi H; Kimura M; Sano M; Nakagomi H; Maeno K; Hama Y; Shingu K; Tsuchiya S; Kohno K; Fujimori M
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8837-44. PubMed ID: 16361573
[TBL] [Abstract][Full Text] [Related]
9. Pranlukast Antagonizes CD49f and Reduces Stemness in Triple-Negative Breast Cancer Cells.
Velázquez-Quesada I; Ruiz-Moreno AJ; Casique-Aguirre D; Aguirre-Alvarado C; Cortés-Mendoza F; de la Fuente-Granada M; García-Pérez C; Pérez-Tapia SM; González-Arenas A; Segura-Cabrera A; Velasco-Velázquez MA
Drug Des Devel Ther; 2020; 14():1799-1811. PubMed ID: 32494122
[TBL] [Abstract][Full Text] [Related]
10. The phosphoinositide-dependent kinase-1 inhibitor 2-amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-acetamide (OSU-03012) prevents Y-box binding protein-1 from inducing epidermal growth factor receptor.
To K; Zhao Y; Jiang H; Hu K; Wang M; Wu J; Lee C; Yokom DW; Stratford AL; Klinge U; Mertens PR; Chen CS; Bally M; Yapp D; Dunn SE
Mol Pharmacol; 2007 Sep; 72(3):641-52. PubMed ID: 17595327
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy.
Stratford AL; Habibi G; Astanehe A; Jiang H; Hu K; Park E; Shadeo A; Buys TP; Lam W; Pugh T; Marra M; Nielsen TO; Klinge U; Mertens PR; Aparicio S; Dunn SE
Breast Cancer Res; 2007; 9(5):R61. PubMed ID: 17875215
[TBL] [Abstract][Full Text] [Related]
12. The strand separation and nuclease activities associated with YB-1 are dispensable for cisplatin resistance but overexpression of YB-1 in MCF7 and MDA-MB-231 breast tumor cells generates several chemoresistance signatures.
Guay D; Evoy AA; Paquet E; Garand C; Bachvarova M; Bachvarov D; Lebel M
Int J Biochem Cell Biol; 2008; 40(11):2492-507. PubMed ID: 18571458
[TBL] [Abstract][Full Text] [Related]
13. The phenotypic radiation resistance of CD44+/CD24(-or low) breast cancer cells is mediated through the enhanced activation of ATM signaling.
Yin H; Glass J
PLoS One; 2011; 6(9):e24080. PubMed ID: 21935375
[TBL] [Abstract][Full Text] [Related]
14. Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability.
Law JH; Li Y; To K; Wang M; Astanehe A; Lambie K; Dhillon J; Jones SJ; Gleave ME; Eaves CJ; Dunn SE
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20844753
[TBL] [Abstract][Full Text] [Related]
15. Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency.
Atkinson RL; Yang WT; Rosen DG; Landis MD; Wong H; Lewis MT; Creighton CJ; Sexton KR; Hilsenbeck SG; Sahin AA; Brewster AM; Woodward WA; Chang JC
Breast Cancer Res; 2013; 15(5):R77. PubMed ID: 24008095
[TBL] [Abstract][Full Text] [Related]
16. FOLFOX Therapy Induces Feedback Upregulation of CD44v6 through YB-1 to Maintain Stemness in Colon Initiating Cells.
Ghatak S; Hascall VC; Markwald RR; Misra S
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33451103
[TBL] [Abstract][Full Text] [Related]
17. Verteporfin targeting YAP1/TAZ-TEAD transcriptional activity inhibits the tumorigenic properties of gastric cancer stem cells.
Giraud J; Molina-Castro S; Seeneevassen L; Sifré E; Izotte J; Tiffon C; Staedel C; Boeuf H; Fernandez S; Barthelemy P; Megraud F; Lehours P; Dubus P; Varon C
Int J Cancer; 2020 Apr; 146(8):2255-2267. PubMed ID: 31489619
[TBL] [Abstract][Full Text] [Related]
18. Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells.
Basaki Y; Hosoi F; Oda Y; Fotovati A; Maruyama Y; Oie S; Ono M; Izumi H; Kohno K; Sakai K; Shimoyama T; Nishio K; Kuwano M
Oncogene; 2007 Apr; 26(19):2736-46. PubMed ID: 17072343
[TBL] [Abstract][Full Text] [Related]
19. YB-1 regulates Sox2 to coordinately sustain stemness and tumorigenic properties in a phenotypically distinct subset of breast cancer cells.
Jung K; Wu F; Wang P; Ye X; Abdulkarim BS; Lai R
BMC Cancer; 2014 May; 14():328. PubMed ID: 24885403
[TBL] [Abstract][Full Text] [Related]
20. Isobavachalcone sensitizes cells to E2-induced paclitaxel resistance by down-regulating CD44 expression in ER+ breast cancer cells.
Shi J; Chen Y; Chen W; Tang C; Zhang H; Chen Y; Yang X; Xu Z; Wei J; Chen J
J Cell Mol Med; 2018 Nov; 22(11):5220-5230. PubMed ID: 30179299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
